Corporate Profile
Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 trials that is being developed for the treatment of Demodex blepharitis.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
News Releases
Oct 20, 2020
Oct 15, 2020
Oct 06, 2020
Events
More events are coming soon.
SEC Filings
| Filing date | Description | Form |
|---|---|---|
Report of unscheduled material events or corporate event |
8-K | |
Securities offered to employees pursuant to employee benefit plans |
S-8 | |
Statement of changes in beneficial ownership of securities |
4 |